微小残存疾患の世界市場レポート 2025年

微小残存疾患市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）12.5％で32億2,000万米ドルに成長します。予測期間の成長は、がん患者数の増加、政府による啓発プログラムの増加、ヘルスケアの低価格化、新興国での可処分所得の増加、政府機関によるがん啓発の取り組みなどに起因しています。この期間に予想される主な動向には、次世代シーケンシング（NGS）技術の進歩、MRD検査の標準化、個別化MRDモニタリングの採用、リキッドバイオプシー技術の開発、微小残存疾患指向型療法の出現などがあります。

がんの有病率の増加は、今後数年間の微小残存疾患（MRD）市場の拡大を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患群を包含します。高齢化、環境発がん物質へのさらなる曝露、不健康なライフスタイル、遺伝的素因など、がんの有病率上昇にはいくつかの要因が関与しています。がん患者数の増加により、残存がん細胞を検出し、早期介入と個別化治療を可能にする精密なMRD検査に対する需要が高まっています。その結果、再発予測が強化され、患者の転帰が改善されます。例えば、2024年5月、米国の政府機関である国立がん研究所（NCI）は、2022年に世界で約2,000万人の新規がん患者と970万人のがん関連死が発生したと報告しました。2040年の予測では、2,990万人が新たにがんに罹患し、1,530万人ががんに関連して死亡すると推定されています。その結果、がん罹患率の増加がMRD市場の成長に拍車をかけています。

MRD市場の主要企業は、個別化治療の選択肢を提供し、患者の転帰を改善するために、先進的な体外診断（IVD）検査サービスの開発を優先しています。IVD検査サービスは、治療後に残存するがん細胞を検出し、再発予測や治療の最適化を支援するために設計された検査室ベースの診断法です。例えば、米国のバイオテクノロジー企業Adaptive Biotechnologies Corporationは2022年12月、びまん性大細胞型B細胞リンパ腫（DLBCL）患者のMRDを検出するclonoSEQ Assayを発表しました。この検査は、血液検体中の循環腫瘍DNA（ctDNA）を分析するもので、がんの進行をモニターし、再発の早期徴候を特定するための高感度で非侵襲的な方法を提供します。臨床医に患者の疾患負担をより正確に評価することで、この検査法はオーダーメイドの治療計画を導くのに役立ちます。特筆すべきは、DLBCLに対するMRD検査として初めてメディケアの保険適用を受け、あらゆる治療レジメンと時点において広く利用できるようになったことです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界微小残存疾患PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の微小残存疾患市場：成長率分析
• 世界の微小残存疾患市場の実績：規模と成長, 2019-2024
• 世界の微小残存疾患市場の予測：規模と成長, 2024-2029, 2034F
• 世界微小残存疾患総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の微小残存疾患市場検出対象別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リンパ腫
• 白血病
• 固形腫瘍
• その他の検出対象
• 世界の微小残存疾患市場テストテクニック別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フローサイトメトリー
• ポリメラーゼ連鎖反応（PCR）
• 次世代シーケンシング（NGS）
• その他のテスト手法
• 世界の微小残存疾患市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 銀行、金融サービス、保険（BFSI）
• 小売業とeコマース
• 病院
• 診断検査室
• 調査機関
• 世界の微小残存疾患市場リンパ腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホジキンリンパ腫
• 非ホジキンリンパ腫
• 世界の微小残存疾患市場白血病の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性リンパ性白血病
• 急性骨髄性白血病
• 慢性リンパ性白血病
• 慢性骨髄性白血病
• 世界の微小残存疾患市場固形腫瘍の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳がん
• 肺がん
• 大腸がん
• 前立腺がん
• 世界の微小残存疾患市場、その他の検出対象の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多発性骨髄腫
• 神経芽細胞腫
• サルコム

第7章 地域別・国別分析

• 世界の微小残存疾患市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の微小残存疾患市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 微小残存疾患市場：競合情勢
• 微小残存疾患市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Laboratory Corporation of America Holdings（LabCorp）Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sysmex Corporation
• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• Exact Sciences Corporation
• Kite Pharma Inc.
• Natera Inc.
• Foundation Medicine Inc.
• NeoGenomics Inc.
• Guardant Health Inc.
• Grail LLC
• Tempus AI Inc.
• Veracyte Inc.
• Adaptive Biotechnologies Corporation
• Invivoscribe Inc.
• Mission Bio Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 微小残存疾患市場2029：新たな機会を提供する国
• 微小残存疾患市場2029：新たな機会を提供するセグメント
• 微小残存疾患市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Minimal residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment, even when the patient is in clinical remission. Monitoring MRD helps in the early detection of relapse, evaluation of treatment effectiveness, and prediction of recurrence risk. This highly sensitive detection method enables personalized therapies, improving patient outcomes and reducing the chances of relapse.

The primary detection targets for MRD include lymphoma, leukemia, solid tumors, and others. Lymphoma is a type of cancer that originates in the lymphatic system and primarily affects white blood cells called lymphocytes. Various test techniques used for MRD detection include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others. These tests are utilized by multiple end-users, including hospitals, diagnostic laboratories, research institutions, and industries such as banking, financial services, and insurance (BFSI), as well as retail and e-commerce.

The minimal residual disease market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease market statistics, including the minimal residual disease industry global market size, regional shares, competitors with the minimal residual disease market share, detailed minimal residual disease market segments, market trends, and opportunities, and any further data you may need to thrive in the minimal residual disease industry. This minimal residual disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth during the historic period can be attributed to the increasing number of cancer patients, growing research and development spending, rising healthcare affordability, the rising prevalence of blood cancer, and increasing awareness among people.

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to the rising number of cancer patients, an increase in government awareness programs, improved healthcare affordability, growing disposable income in emerging economies, and initiatives by government bodies to raise cancer awareness. Key trends expected during this period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, the adoption of personalized MRD monitoring, developments in liquid biopsy technologies, and the emergence of minimal residual disease-directed therapies.

The growing prevalence of cancer is anticipated to drive the expansion of the minimal residual disease (MRD) market in the coming years. Cancer encompasses a group of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. Several factors contribute to the increasing prevalence of cancer, including an aging population, greater exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising number of cancer cases has led to a growing demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This, in turn, enhances relapse prediction and improves patient outcomes. For example, in May 2024, the National Cancer Institute (NCI), a US-based government agency, reported that nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022. Projections for 2040 estimate 29.9 million new cases and 15.3 million cancer-related deaths. As a result, the increasing cancer prevalence is fueling the growth of the MRD market.

Leading companies in the MRD market are prioritizing the development of advanced in vitro diagnostic (IVD) test services to offer personalized therapy options and improve patient outcomes. IVD test services are laboratory-based diagnostic methods designed to detect residual cancer cells following treatment, aiding in relapse prediction and therapy optimization. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, introduced the clonoSEQ Assay for detecting MRD in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples, providing a highly sensitive, non-invasive method for monitoring cancer progression and identifying early signs of relapse. By offering clinicians a more precise assessment of a patient's disease burden, the assay helps guide tailored treatment plans. Notably, it is the first MRD test for DLBCL to receive Medicare coverage, ensuring broad accessibility across all treatment regimens and time points.

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. This acquisition incorporates C2i Genomics' whole-genome MRD expertise into Veracyte's diagnostic platform, enhancing its ability to support patients at various stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company specializing in minimal residual disease (MRD) testing.

Major players in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in minimal residual disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the minimal residual disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Minimal Residual Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on minimal residual disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for minimal residual disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The minimal residual disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Detection Target: Lymphoma; Leukemia; Solid Tumors; Other Detection Targets
• 2) By Test Technique: Flow Cytometry; Polymerase Chain Reaction (PCR); Next Generation Sequencing (NGS); Other Test Techniques
• 3) By End-User: Banking, Financial Services, And Insurance (BFSI); Retail And E-Commerce; Hospitals; Diagnostic Laboratories; Research Institutions
• Subsegments:
• 1) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma
• 2) By Leukemia: Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Myeloid Leukemia
• 3) By Solid Tumors: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer
• 4) By Other Detection Targets: Multiple Myeloma; Neuroblastoma; Sarcomas
• Companies Mentioned: Thermo Fisher Scientific Inc.; Amgen Inc.; Laboratory Corporation of America Holdings (LabCorp); Quest Diagnostics Incorporated; Agilent Technologies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Minimal Residual Disease Market Characteristics

3. Minimal Residual Disease Market Trends And Strategies

4. Minimal Residual Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Minimal Residual Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Minimal Residual Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Minimal Residual Disease Market Growth Rate Analysis
• 5.4. Global Minimal Residual Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Minimal Residual Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Minimal Residual Disease Total Addressable Market (TAM)

6. Minimal Residual Disease Market Segmentation

• 6.1. Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lymphoma
• Leukemia
• Solid Tumors
• Other Detection Targets
• 6.2. Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Flow Cytometry
• Polymerase Chain Reaction (PCR)
• Next Generation Sequencing (NGS)
• Other Test Techniques
• 6.3. Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Banking, Financial Services, And Insurance (BFSI)
• Retail And E-Commerce
• Hospitals
• Diagnostic Laboratories
• Research Institutions
• 6.4. Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• 6.5. Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Chronic Myeloid Leukemia
• 6.6. Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• 6.7. Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Multiple Myeloma
• Neuroblastoma
• Sarcom

7. Minimal Residual Disease Market Regional And Country Analysis

• 7.1. Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Minimal Residual Disease Market

• 8.1. Asia-Pacific Minimal Residual Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Minimal Residual Disease Market

• 9.1. China Minimal Residual Disease Market Overview
• 9.2. China Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Minimal Residual Disease Market

• 10.1. India Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Minimal Residual Disease Market

• 11.1. Japan Minimal Residual Disease Market Overview
• 11.2. Japan Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Minimal Residual Disease Market

• 12.1. Australia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Minimal Residual Disease Market

• 13.1. Indonesia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Minimal Residual Disease Market

• 14.1. South Korea Minimal Residual Disease Market Overview
• 14.2. South Korea Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Minimal Residual Disease Market

• 15.1. Western Europe Minimal Residual Disease Market Overview
• 15.2. Western Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Minimal Residual Disease Market

• 16.1. UK Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Minimal Residual Disease Market

• 17.1. Germany Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Minimal Residual Disease Market

• 18.1. France Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Minimal Residual Disease Market

• 19.1. Italy Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Minimal Residual Disease Market

• 20.1. Spain Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Minimal Residual Disease Market

• 21.1. Eastern Europe Minimal Residual Disease Market Overview
• 21.2. Eastern Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Minimal Residual Disease Market

• 22.1. Russia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Minimal Residual Disease Market

• 23.1. North America Minimal Residual Disease Market Overview
• 23.2. North America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Minimal Residual Disease Market

• 24.1. USA Minimal Residual Disease Market Overview
• 24.2. USA Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Minimal Residual Disease Market

• 25.1. Canada Minimal Residual Disease Market Overview
• 25.2. Canada Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Minimal Residual Disease Market

• 26.1. South America Minimal Residual Disease Market Overview
• 26.2. South America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Minimal Residual Disease Market

• 27.1. Brazil Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Minimal Residual Disease Market

• 28.1. Middle East Minimal Residual Disease Market Overview
• 28.2. Middle East Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Minimal Residual Disease Market

• 29.1. Africa Minimal Residual Disease Market Overview
• 29.2. Africa Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Minimal Residual Disease Market Competitive Landscape And Company Profiles

• 30.1. Minimal Residual Disease Market Competitive Landscape
• 30.2. Minimal Residual Disease Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Laboratory Corporation of America Holdings (LabCorp) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Minimal Residual Disease Market Other Major And Innovative Companies

• 31.1. Sysmex Corporation
• 31.2. Bio-Rad Laboratories Inc.
• 31.3. Qiagen N.V.
• 31.4. Exact Sciences Corporation
• 31.5. Kite Pharma Inc.
• 31.6. Natera Inc.
• 31.7. Foundation Medicine Inc.
• 31.8. NeoGenomics Inc.
• 31.9. Guardant Health Inc.
• 31.10. Grail LLC
• 31.11. Tempus AI Inc.
• 31.12. Veracyte Inc.
• 31.13. Adaptive Biotechnologies Corporation
• 31.14. Invivoscribe Inc.
• 31.15. Mission Bio Inc.

32. Global Minimal Residual Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Market

34. Recent Developments In The Minimal Residual Disease Market

35. Minimal Residual Disease Market High Potential Countries, Segments and Strategies

• 35.1 Minimal Residual Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Minimal Residual Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Minimal Residual Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer